Your browser doesn't support javascript.
loading
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
George, Daniel J; Halabi, Susan; Heath, Elisabeth I; Sartor, A Oliver; Sonpavde, Guru P; Das, Devika; Bitting, Rhonda L; Berry, William; Healy, Patrick; Anand, Monika; Winters, Carol; Riggan, Colleen; Kephart, Julie; Wilder, Rhonda; Shobe, Kellie; Rasmussen, Julia; Milowsky, Matthew I; Fleming, Mark T; Bearden, James; Goodman, Michael; Zhang, Tian; Harrison, Michael R; McNamara, Megan; Zhang, Dadong; LaCroix, Bonnie L; Kittles, Rick A; Patierno, Brendon M; Sibley, Alexander B; Patierno, Steven R; Owzar, Kouros; Hyslop, Terry; Freedman, Jennifer A; Armstrong, Andrew J.
Affiliation
  • George DJ; Department of Medicine, Division of Medical Oncology, Duke University, Durham, North Carolina.
  • Halabi S; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Heath EI; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Sartor AO; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
  • Sonpavde GP; Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
  • Das D; Tulane Cancer Center, Tulane Health Sciences Center, New Orleans, Louisiana.
  • Bitting RL; Hematology and Oncology Division, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama.
  • Berry W; Hematology and Oncology Division, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama.
  • Healy P; Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina.
  • Anand M; Department of Medicine, Division of Medical Oncology, Duke University, Durham, North Carolina.
  • Winters C; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Riggan C; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Kephart J; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Wilder R; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Shobe K; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Rasmussen J; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Milowsky MI; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Fleming MT; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Bearden J; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Goodman M; Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Zhang T; Virginia Oncology Associates, Hampton, Virginia.
  • Harrison MR; Gibbs Cancer Center, Spartanburg, South Carolina.
  • McNamara M; W.G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina.
  • Zhang D; Department of Medicine, Division of Medical Oncology, Duke University, Durham, North Carolina.
  • LaCroix BL; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Kittles RA; Department of Medicine, Division of Medical Oncology, Duke University, Durham, North Carolina.
  • Patierno BM; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Sibley AB; Department of Medicine, Division of Medical Oncology, Duke University, Durham, North Carolina.
  • Patierno SR; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Owzar K; Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina.
  • Hyslop T; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
  • Freedman JA; Department of Population Sciences, Division of Health Equities, City of Hope National Medical Center, Duarte, California.
  • Armstrong AJ; Center for Prostate and Urologic Cancers, Duke Cancer Institute, Duke University, Durham, North Carolina.
Cancer ; 127(16): 2954-2965, 2021 08 15.
Article in En | MEDLINE | ID: mdl-33951180
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / Abiraterone Acetate Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Cancer Year: 2021 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / Abiraterone Acetate Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: Cancer Year: 2021 Type: Article